top of page

Visiting Adaptimmune on its investor day and ahead of this year's FDA decision for the TCR cell therapy afami-cel in synovial sarcoma

Apr 18, 2024
1 min read

CEO Adrian Rawcliffe describes how Adaptimmune is preparing to launch what could be the first approved TCR based cell therapy in the United States and what the potential launch means for the company.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page